Aldoxorubicin is under clinical development by ImmunityBio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Aldoxorubicin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aldoxorubicin (INNO-206, DOXO-EMCH, doxorubicin-EMCH) is under development for the treatment of solid tumors including advanced soft tissue sarcoma, triple-negative breast cancer, metastatic pancreatic cancer, metastatic small cell lung cancer (SCLC), glioblastoma multiforme and ovarian cancer, Bone cancer including rhabdomyosarcoma, Ewing's sarcoma and mixed mesodermal sarcoma), chondrosarcoma or osteosarcoma of intermediate or high grade, gastrointestinal stromal tumors and advanced squamous cell carcinoma (SCC) as head and neck or non-small cell lung cancer, relapsed and refractory colorectal cancer. The drug candidate is administered as an intravenous infusion. The drug candidate targets DNA synthesis. Aldoxorubicin is a tumor-targeted doxorubicin conjugate. The drug candidate is a (6-Maleimidocaproyl) hydrazone of doxorubicin. It is based on conjugated tumor-targeted technology. INNO-206 is a chemically modified version of doxorubicin that incorporates an acid sensitive linker technology to improve targeting to the tumor. It was also under development for the treatment of metastatic pancreatic ductal adenocarcinoma.
It was also under the development for the treatment of kaposi sarcoma.
ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.
For a complete picture of Aldoxorubicin’s drug-specific PTSR and LoA scores, buy the report here.